Vimarsana
Biggest News Aggregation in the World

Page 44 - Share Repurchase Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Share Repurchase Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Share Repurchase Program Today - Breaking & Trending Today

Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023 - Vimarsana News

Azenta Reports First Quarter Results for Fiscal 2024, Ended December 31, 2023

/PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the first quarter ended December 31, 2023. Quarter Ended Dollars in millions,...

Lear Corp (LEA) Posts Record Sales and Robust Earnings Growth in 2023 - Vimarsana News

Lear Corp (LEA) Posts Record Sales and Robust Earnings Growth in 2023

Full Year Sales Surge 12% with Significant Share Repurchases

Source: yahoo.com
CTS Announces Fourth Quarter and Full-Year 2023 Results - Vimarsana News

CTS Announces Fourth Quarter and Full-Year 2023 Results

Building Momentum on Long-term Strategy While Navigating Near-term ChallengesAnnounces $100 million Share Repurchase Program LISLE, Ill., Feb. 06, 2024 -- CTS Corporation , a leading global...

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update - Vimarsana News

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

- Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 million in U.S. Net Product Revenues for the...

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update - Vimarsana News

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Exelixis, Inc. today reported financial results for the fourth quarter and fiscal year of 2023, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones....